Clinical Trials Browser

Phase 1 × NETWORK × Irinotecan × Clear all

NCT02975882 2025-01-14

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 1 Completed

33 enrolled 15 charts

Central Nervous System Neoplasms

NCT03323034 2024-10-22

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Phase 1 Completed

30 enrolled 19 charts

Lymphoma, Central Nervous System Neoplasms

NCT00138216 2023-10-02

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

Phase 1 Completed

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma

NCT00535353 2023-08-04

AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00059761 2015-11-17

Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Phase 1 Completed

Lung Neoplasms

NCT00008424 2014-05-05

Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants

Phase 1 Completed

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00006095 2014-02-21

Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

Phase 1 Completed

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific